(Q46781537)

25 December 2017

title

Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics (English)

1 reference

25 December 2017

1 reference

1 reference

1 reference

Jacques Gaudreault

1

1 reference

25 December 2017

Vanessa Shiu

2

1 reference

25 December 2017

Ann Bricarello

3

1 reference

25 December 2017

Brian J Christian

4

1 reference

25 December 2017

Christina L Zuch

5

1 reference

25 December 2017

Barbara Mounho

6

1 reference

25 December 2017

publication date

1 September 2005

1 reference

25 December 2017

International Journal of Toxicology

published in

1 reference

25 December 2017

volume

24

1 reference

25 December 2017

issue

5

1 reference

25 December 2017

page(s)

357-363

1 reference

25 December 2017

New approaches to prevent intestinal toxicity of irinotecan-based regimens

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10915810500209353

Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810500209353

Clinical pharmacology of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810500209353

New Tables for Multiple Comparisons with a Control

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810500209353

Role of vascular endothelial growth factor in the regulation of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810500209353

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810500209353

Multiple roles for the major histocompatibility complex class I- related receptor FcRn

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810500209353

Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810500209353

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810500209353

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810500209353

Tumor angiogenesis and accessibility: role of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810500209353

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810500209353

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810500209353

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810500209353

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810500209353

Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810500209353

10.1080/10915810500209353

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

PubMed ID

16257855

1 reference

25 December 2017